Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Buccal fat pad-derived stem cells (BFPSCs) are a population of multipotent mesenchymal stem cells (MSCs) harvested from the buccal fat pad, a specialized adipose tissue in the cheek. These cells are highly valued in regenerative medicine, particularly in oral and maxillofacial surgery, due to their ease of access through a minimally invasive procedure, low donor-site morbidity, and robust osteogenic (bone-forming) and angiogenic (blood vessel-forming) potential. BFPSCs work by differentiating into osteoblasts and cementoblasts while secreting essential growth factors such as bone morphogenetic protein 2 (BMP-2) and vascular endothelial growth factor (VEGF), which facilitate the repair of critical-size bone defects and alveolar ridge augmentation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on buccal fat pad-derived stem cells.